杜瓦卢马布
胆管癌
医学
化疗
胆道癌
肿瘤科
癌症
内科学
免疫疗法
吉西他滨
无容量
作者
Yun‐Xin Lu,Jia Yin,Furong Liu,Zixian Wang,Wen Zhou,Yang Zhang,Bing Bai,Xiaogang Wang,Zhiqiang Wang,Min Nie,Hui Luo,Xiaoli Wei,Chuqiao Liang,Guifang Guo,Miao‐Zhen Qiu,Jianwen Chen,Y. Liu,Shengping Li,Yanhua Li,Fenghua Wang,Xiaogang Wang,Peidong Chi,Dongsheng Zhang
标识
DOI:10.1007/s00262-024-03796-1
摘要
The anti-PD-L1 antibody durvalumab has been approved for use in first-line advanced biliary duct cancer (ABC). So far, predictive biomarkers of efficacy are lacking.
科研通智能强力驱动
Strongly Powered by AbleSci AI